Chuck Grassley

United States Senator from Iowa

Instagram

Flickr

Twitter

Facebook

Grassley works to empower whistleblowers, protect tax dollars

Jul 01, 2010


Grassley works to empower whistleblowers, protect tax dollars


M E M O R A N D U M

 

TO: Reporters and Editors FR: Jill Kozeny, 202-224-1308  for Senator Chuck Grassley RE: whistleblower protections for drug company employees DA: July 1, 2010

 

Senator Chuck Grassley has sent letters to 16 pharmaceutical companies about the False Claims Act, which offers whistleblower protections to private-sector employees who identify fraud against the taxpayers.

 

Grassley said, “The False Claims Act is a proven success in both identifying and deterring fraud and recovering fraudulently obtained taxpayer dollars. The more that can be done to create awareness of it, the more good it can do. My appeal to drug makers is based on the fact that they have a public responsibility to safeguard the tax dollars that pay for their products, and promoting a culture where those who speak up about possible fraud are rewarded rather than retaliated against is one way to fulfill that responsibility. In the last three years, Pharmaceutical companies have paid out over $3 billion in settlements under the False Claims Act for defrauding federal health care programs. There can never be too many taxpayer watchdogs, so I see this letter as an opportunity to foster a mindset that recognizes the value of whistleblowers and the duty these companies have to act honestly when seeking taxpayer dollars.”

 

Recent False Claims Act settlements with pharmaceutical manufacturers include:

 

Astra Zeneca -- $520 million -- April 2010 Pfizer -- $2.3 billion ($1 billion under FCA, $1.3 billion criminal) -- September 2009 Eli Lily -- $1.4 billion -- January 2009 Bristol Myers Squibb -- $515 million -- 2007

 

 Below are links to the letters sent by Grassley to:

 

Abbott Laboratories  

Amgen  

AstraZeneca Pharmaceuticals  

Bristol-Myers Squibb Company  

Eisai Corporation of America  

Eli Lilly and Company  

Forest Laboratories  

GlaxoSmithKline  

Hoffman-La Roche Inc.  

Johnson & Johnson  

Merck & Co.  

Novartis  

Pfizer  

Sanofi-Aventis  

Takeda Pharmaceuticals  

Boehringer

 

Grassley co-authored the 1986 updates to the False Claims Act, which breathed new life into what is known as Abe Lincoln’s Law by empowering qui tam relators to act as private attorneys general and file suit against those who defraud the federal government. President Lincoln sought the False Claims Act during the Civil War in response to war profiteering that defrauded U.S. taxpayers. Since the modern-day changes made by Grassley’s amendments in 1986, the law has recovered more than $22 billion that would otherwise have been lost to fraud. It has become the government’s most effective weapon against fraud, including health care fraud.